PROSPER, TX - July 16, 2026 - PRESSADVANTAGE - Pediatric Eye Specialists has released a new educational article titled ...

Results point to potential to restore vision with drugs, non-invasively, reversibly, via a mechanism that is independent to ...

High Lander and Thirdeye launch a multi-aircraft ground-based detect and avoid field program to scale BVLOS drone operations.

Blinding diseases caused by the degeneration of photoreceptors, such as age-related macular degeneration (AMD) and retinitis ...

ZOC2017217, an eye drop aimed at slowing or reversing the development of cataracts, is undergoing a pilot study ahead of a ...

Cerebral (or cortical) visual impairment (CVI) is a brain-based visual disorder that is the leading cause of pediatric visual ...

Dompé, a biopharmaceutical company with operations in Italy and the US, announced the first patient has been enrolled in a Phase 3 study of cenegermin-bkbj for the treatment of non-arteritic anterior ...

Spread the love“`html Every parent hopes their child will flourish physically and academically. Yet, many don’t realize that ...

Alcon and RxSight, Inc have announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting ...

Eyecare company Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating ...

Bausch + Lomb said on Thursday its glaucoma eye drop had missed ​the main goal in a ‌mid-stage trial of replicating visual function improvements observed in a smaller study. The company said it will ...